Evidence map›Paper›PMID 34669098›Full record

ArticleMetabolic brain disease2021

Moringa oleifera-supplemented diet protect against cortico-hippocampal neuronal degeneration in scopolamine-induced spatial memory deficit in mice: role of oxido-inflammatory and cholinergic neurotransmission pathway.

Samuel Adetunji Onasanwo, Vanessa O Adamaigbo, Olusegun G Adebayo, Spiff E Eleazer

Abstract read
PubMed Publisher
In one paragraph

Article in Metabolic brain disease, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
5.5field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 33 citations in OpenAlex.

  1. IBRO neuroscience reports · 2026
    Article
  2. Therapeutic Potential ofJournal of inflammation research · 2026
    Review
  3. Article
  4. Article
  5. Life (Basel, Switzerland) · 2025
    Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. A Review on the Neuroprotective Effect ofOxidative medicine and cellular longevity · 2024
    Review
  12. Frontiers in pharmacology · 2024
    Review
  13. Review
  14. Suppression of Inflamm-Aging byMolecules (Basel, Switzerland) · 2023
    Review
  15. Review
  16. Article
  17. Article
  18. Review
  19. The Oil Formulation Derived fromJournal of experimental pharmacology · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Samuel Adetunji OnasanwoNeurosciences and Oral Physiology Unit, Department of Physiology, Faculty of Basic Medical Sciences, College of Medicine, University of Ibadan, Ibadan, Nigeria. sa.onasanwo@mail.ui.edu.ng.ORCID http://orcid.org/0000-0003-0493-7995
Vanessa O AdamaigboNeurosciences and Oral Physiology Unit, Department of Physiology, Faculty of Basic Medical Sciences, College of Medicine, University of Ibadan, Ibadan, Nigeria.
Olusegun G AdebayoNeurosciences and Oral Physiology Unit, Department of Physiology, Faculty of Basic Medical Sciences, College of Medicine, University of Ibadan, Ibadan, Nigeria.ORCID http://orcid.org/0000-0001-6654-2564
Spiff E EleazerNeurophysiology Unit, Department of Physiology, Faculty of Basic Medical Sciences, PAMO University of Medical Sciences, Port-Harcourt, Nigeria.
University of Ibadan · NGPAMO University of Medical Sciences

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The therapeutic and pharmacological management of Alzheimer's disease (AD) is generally considered a major concern in ethnomedicine. Moreover, plant-based foods containing flavonoids were previously reported to show neuroprotective effects by modulating self-aggregation of amyloid-β (Aβ)/or tau peptide into oligomers and fibrils, associated with the pathogenesis of AD. This study investigated the impact of Moringa oleifera-supplemented diet (MO-SD) in scopolamine-induced spatial memory deficit in mice. Mice were partitioned into two phases with five groups each (n=6) and pretreated intraperitoneally with scopolamine (1 mg/kg) prior the daily oral administration of MO-SD (1 %, 5 % and 10 %) for 7 and 14 days. Spatial memory function was assessed using the Morris water maze (MWM) test. Thereafter, markers of cholinergic system inhibition (Acetylcholinesterase; AChE) and oxido-inflammatory stress (Malonaldehyde, MDA; Nitrite; Superoxide Dismutase, SOD; Tumor necrosis factor-alpha, TNF-α) and histo-morphology of the cortico-hippocampal neuron were measured. The scopolamine treatment led to loss of spatial memory function in mice spatial exploration of the escape platform in the MWM test. Meanwhile, treatment with MO-SD attenuated loss of spatial memory function via significant decrease in escape latency, significant increase in the frequency of cross with time spent in the platform quadrant. Furthermore, scopolamine treatment altered the endogenous antioxidants and pro-inflammatory mediators, elevated acetylcholinesterase activity and promoted chromatolysis of the cortico-hippocampal neuron. However, MO-SD significantly ameliorated oxido-inflammatory stress, restored cholinergic transmission via acetylcholinesterase inhibition and maintains neuronal integrity in the mice brain at both phases. These results suggest that Moringa oleifera-supplemented diet may serve a potential therapeutic and possible pharmacological macromolecule for preventing loss of neuronal cells and management of Alzheimer's disease.

Indexed as

Moringa oleiferaScopolamineAcetylcholinesteraseAnimalsCholinergic AgentsDietHippocampusMaze LearningMemory DisordersMiceOxidative StressSpatial MemorySynaptic TransmissionAcetylcholinesteraseCholinergic AgentsScopolamineCortico-hippocampal neuronInflammatory stressMoringa oleiferaOxidative stressSpatial memory

Identifiers

PMID34669098
OpenAlexW3207108020

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.